Generalized
arterial calcification of infancy (
GACI) is associated with widespread arterial calcification and
stenoses and is caused by mutations in ENPP1. ENPP1 encodes for
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), which cleaves
ATP to generate inorganic
pyrophosphate (PPi) and
adenosine monophosphate (
AMP) extracellularly. The current study was designed to define the prevalence of arterial
stenoses in
GACI individuals and to identify the mechanism through which ENPP1 deficiency causes intimal proliferation. Furthermore, we aimed to effectively prevent and treat
neointima formation in an animal model of
GACI through the systemic administration of recombinant human (rh)ENPP1-Fc
protein. Based on a literature review, we report that arterial
stenoses are present in at least 72.4% of
GACI cases. We evaluated the effect of rhENPP1-Fc on ENPP1-silenced human vascular smooth muscle cells (VSMCs) and on induced intimal proliferation in Enpp1-deficient ttw/ttw mice treated with carotid
ligation. We demonstrate that silencing ENPP1 in VSMCs resulted in a tenfold increase in proliferation relative to that of cells transfected with negative control
siRNA. The addition of rhENPP1-Fc,
AMP or
adenosine restored the silenced ENPP1-associated proliferation. In contrast, neither PPi nor
etidronate, a current off-label treatment for
GACI, had an effect on VSMC proliferation. Furthermore, subcutaneous rhENPP1-Fc
protein replacement was effective in preventing and treating intimal
hyperplasia induced by carotid
ligation in an animal model of
GACI. We conclude that ENPP1 inhibits
neointima formation by generating AMP. RhENPP1-Fc may serve as an approach for the effective prevention and treatment of arterial
stenoses in
GACI.